AngioDynamics Q1 sales beat on med tech segment growth

AngioDynamics

08/10/2026 11:13

Overview
U.S. medical technology firm's fiscal Q1 sales grew 6.9%, slightly beating analyst expectations
Adjusted loss per share and adjusted net loss for Q1 both beat analyst expectations
Company announced CEO transition and received FDA IDE approval for new clinical study

Outlook
Company reiterates fiscal 2027 net sales guidance of $336 mln to $341 mln
Company expects fiscal 2027 adjusted EPS of ($0.29) to ($0.24)
AngioDynamics anticipates fiscal 2027 gross margin of 54% to 55%

Result Drivers
MED TECH SEGMENT - Double-digit growth in Med Tech segment, led by Auryon atherectomy, Mechanical Thrombectomy, and NanoKnife platforms, drove overall sales increase
NANOKNIFE DEMAND - NanoKnife sales rose 29% year-over-year, driven by increased demand for prostate procedures and growth in probes and capital sales
GROSS MARGIN IMPROVEMENT - Gross margin increased due to favorable pricing, revenue mix shift toward Med Tech, and tariff refunds

Company press release: ID:nBw5VcCf2a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Slight Beat*
$80.90 mln
$80.50 mln (4 Analysts)
Q1 Adjusted Loss Per Share
Beat
$0.04
$0.11 (3 Analysts)
Q1 Adjusted Net Loss
Beat
$1.80 mln
$4.81 mln (3 Analysts)
Q1 Net Loss
 
$7.10 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AngioDynamics, Inc. is $19.50, about 37.4% above its October 7 closing price of $14.19

Reuters Recommended Reads
Oct 7 - Medical device maker Centinel Spine discloses revenue rise in US IPO filing
Oct 6 - Becton Dickinson pledges $19 billion US investment in deal with government
Oct 5 - GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)